195 related articles for article (PubMed ID: 10937606)
1. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
Weiner MF; Martin-Cook K; Foster BM; Saine K; Fontaine CS; Svetlik DA
J Clin Psychiatry; 2000 Jul; 61(7):487-92. PubMed ID: 10937606
[TBL] [Abstract][Full Text] [Related]
2. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
[TBL] [Abstract][Full Text] [Related]
3. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
5. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
Mizuno S; Kameda A; Inagaki T; Horiguchi J
Psychiatry Clin Neurosci; 2004 Dec; 58(6):660-5. PubMed ID: 15601392
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients.
Nobili F; Vitali P; Canfora M; Girtler N; De Leo C; Mariani G; Pupi A; Rodriguez G
Clin Neurophysiol; 2002 Aug; 113(8):1241-8. PubMed ID: 12140003
[TBL] [Abstract][Full Text] [Related]
7. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
[TBL] [Abstract][Full Text] [Related]
8. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
Cummings JL; McRae T; Zhang R;
Am J Geriatr Psychiatry; 2006 Jul; 14(7):605-12. PubMed ID: 16816014
[TBL] [Abstract][Full Text] [Related]
9. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.
Samuel W; Caligiuri M; Galasko D; Lacro J; Marini M; McClure FS; Warren K; Jeste DV
Int J Geriatr Psychiatry; 2000 Sep; 15(9):794-802. PubMed ID: 10984725
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
11. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
[TBL] [Abstract][Full Text] [Related]
12. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
13. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease.
Paleacu D; Mazeh D; Mirecki I; Even M; Barak Y
Clin Neuropharmacol; 2002; 25(6):313-7. PubMed ID: 12469005
[TBL] [Abstract][Full Text] [Related]
14. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
16. Comparison of functional and cognitive donepezil effects in Alzheimer's disease.
Saine K; Cullum CM; Martin-Cook K; Hynan L; Svetlik DA; Weiner MF
Int Psychogeriatr; 2002 Jun; 14(2):181-5. PubMed ID: 12243208
[TBL] [Abstract][Full Text] [Related]
17. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of donepezil in Alzheimer's disease].
Ito T; Yamadera H
J Nippon Med Sch; 2002 Aug; 69(4):379-82. PubMed ID: 12187372
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
[TBL] [Abstract][Full Text] [Related]
20. Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease.
Dallocchio C; Buffa C; Mazzarello P
J Clin Psychiatry; 2000 Jan; 61(1):64. PubMed ID: 10695652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
